- Home
- WTTR vs DNTH Comparison
WTTR vs DNTH Comparison
Compare WTTR & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WTTR
- DNTH
- Stock Information
- Founded
- WTTR 2016
- DNTH 2015
- Country
- WTTR United States
- DNTH United States
- Employees
- WTTR N/A
- DNTH N/A
- Industry
- WTTR Oilfield Services/Equipment
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- WTTR Energy
- DNTH Health Care
- Exchange
- WTTR Nasdaq
- DNTH Nasdaq
- Market Cap
- WTTR 922.1M
- DNTH 780.2M
- IPO Year
- WTTR 2017
- DNTH N/A
- Fundamental
- Price
- WTTR $8.41
- DNTH $26.50
- Analyst Decision
- WTTR Strong Buy
- DNTH Strong Buy
- Analyst Count
- WTTR 3
- DNTH 8
- Target Price
- WTTR $15.00
- DNTH $54.00
- AVG Volume (30 Days)
- WTTR 979.2K
- DNTH 374.5K
- Earning Date
- WTTR 11-04-2025
- DNTH 11-06-2025
- Dividend Yield
- WTTR 3.34%
- DNTH N/A
- EPS Growth
- WTTR N/A
- DNTH N/A
- EPS
- WTTR 0.32
- DNTH N/A
- Revenue
- WTTR $1,458,995,000.00
- DNTH $4,854,000.00
- Revenue This Year
- WTTR N/A
- DNTH N/A
- Revenue Next Year
- WTTR $0.71
- DNTH N/A
- P/E Ratio
- WTTR $26.03
- DNTH N/A
- Revenue Growth
- WTTR N/A
- DNTH 17.87
- 52 Week Low
- WTTR $7.20
- DNTH $13.37
- 52 Week High
- WTTR $15.14
- DNTH $32.27
- Technical
- Relative Strength Index (RSI)
- WTTR 47.09
- DNTH 70.68
- Support Level
- WTTR $8.29
- DNTH $22.81
- Resistance Level
- WTTR $8.73
- DNTH $24.81
- Average True Range (ATR)
- WTTR 0.27
- DNTH 1.57
- MACD
- WTTR 0.07
- DNTH 0.22
- Stochastic Oscillator
- WTTR 63.01
- DNTH 91.57
About WTTR Select Water Solutions Inc.
Select Water Solutions Inc provides sustainable water and chemical solutions to the energy industry. These solutions are supported by the company's critical water infrastructure assets, chemical manufacturing, and water treatment and recycling capabilities. Its reportable segments are Water Services, Water Infrastructure and Chemical Technologies. It generates the majority of its revenue from Water Services segment.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.